Alpha-lipoic acid (ALA) is a naturally occurring antioxidant synthesized in small amounts by the body and available as a dietary supplement. It functions as a cofactor in mitochondrial energy metabolism, scavenges free radicals, chelates metals, restores glutathione levels, and can cross the blood-brain barrier. ALA is clinically used for diabetic neuropathy and studied for its potential anti-aging, neuroprotective, and metabolic benefits.

Overview

Alpha-lipoic acid (ALA), also known as thioctic acid, is a naturally occurring dithiol compound synthesized in small quantities by mitochondrial lipoic acid synthase. It serves as an essential cofactor for mitochondrial α-keto acid dehydrogenase complexes, including pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, making it integral to aerobic energy metabolism. Uniquely among biological antioxidants, ALA is amphiphilic (active in both aqueous and lipid environments) and can regenerate other antioxidants including vitamins C and E, coenzyme Q10, and glutathione.

The strongest clinical evidence for ALA supplementation exists for diabetic peripheral neuropathy. The SYDNEY, NATHAN, and ALADIN trials demonstrated that intravenous ALA (600 mg/day) significantly improved neuropathic symptoms including pain, burning, and numbness compared to placebo. Oral supplementation at 600 mg/day has also shown benefit, though with somewhat slower onset. In Germany, ALA has been an approved treatment for diabetic neuropathy for several decades. Additional research has explored ALA for weight management, insulin sensitivity, non-alcoholic fatty liver disease, and multiple sclerosis, with varying levels of evidence.

Commercially available ALA supplements contain a racemic mixture of R-lipoic acid (the biologically active enantiomer) and S-lipoic acid, though pure R-lipoic acid formulations are also available at premium cost. Typical oral doses range from 300 to 600 mg daily. ALA is generally well tolerated, with nausea and skin rash being the most common side effects. It can lower blood glucose levels, so individuals taking antidiabetic medications should monitor blood sugar carefully to avoid hypoglycemia.

Mechanism of Action

Redox Cycling & Universal Antioxidant

Alpha-lipoic acid (ALA) is a dithiol compound that functions as a cofactor and potent redox agent. Both ALA and its reduced form dihydrolipoic acid (DHLA) are active, creating a redox couple that scavenges hydroxyl radicals, hypochlorous acid, peroxynitrite, and singlet oxygen. Uniquely, this pair operates in both aqueous and lipid environments, enabling protection across all cellular compartments (PMID: 7649494).

Antioxidant Network Regeneration

DHLA regenerates other antioxidants from their oxidized forms: it reduces dehydroascorbate back to vitamin C, recycles oxidized glutathione (GSSG) to GSH via non-enzymatic thiol-disulfide exchange, and regenerates alpha-tocopherol (vitamin E) indirectly through ascorbate recycling. ALA also upregulates intracellular glutathione synthesis by enhancing cystine uptake via the xc- transporter and activating Nrf2-ARE signaling (PMID: 12489095).

Mitochondrial Cofactor Function

ALA is an essential cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes, where it serves as the acyl group carrier in oxidative decarboxylation reactions. This role directly supports mitochondrial energy metabolism and substrate flux through the TCA cycle (PMID: 9284364).

Insulin Signaling & Glucose Metabolism

ALA enhances glucose uptake by activating AMPK (AMP-activated protein kinase) and stimulating GLUT4 translocation to the plasma membrane in skeletal muscle and adipocytes. It also improves insulin receptor substrate-1 (IRS-1) phosphorylation and PI3K/Akt signaling, reducing insulin resistance (PMID: 16873688).

Anti-Inflammatory & Metal Chelation

ALA chelates transition metals (Fe²⁺, Cu²⁺, Zn²⁺) that catalyze Fenton reactions, and inhibits NF-kB activation by maintaining IkB-alpha stability, reducing downstream inflammatory cytokine production.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Alpha Lipoic Acid (ALA/Thioctic Acid)

Common Side Effects

• GI effects (most common): Nausea, vomiting, diarrhea, abdominal discomfort — dose-related, more frequent above 600 mg/day
• Dermatologic: Skin rash, urticaria, pruritus
• CNS: Headache, dizziness, paresthesias (tingling)
• Metabolic: Hypoglycemia (due to insulin-sensitizing effects), particularly in diabetic patients

Serious Adverse Effects

• Insulin autoimmune syndrome (IAS/Hirata disease): Rare but serious; primarily reported in Japanese and Korean populations with specific HLA genotypes (HLA-DRB1*0406) — presents as severe hypoglycemia
• Allergic reactions: Anaphylaxis reported rarely
• Hepatotoxicity: Rare cases of elevated liver enzymes

Contraindications

• Known hypersensitivity to alpha lipoic acid
• History of insulin autoimmune syndrome
• Caution in thiamine (B1) deficiency — ALA may worsen deficiency-related conditions
• Heavy alcohol use (increased risk of thiamine depletion)

Drug Interactions

• Insulin/oral hypoglycemics: ALA enhances insulin sensitivity; dose adjustments of diabetic medications may be needed to prevent hypoglycemia
• Thyroid hormones (levothyroxine): ALA may reduce circulating T3/T4 levels; monitor thyroid function
• Cisplatin/other platinum agents: ALA may reduce chemotherapy efficacy as an antioxidant — avoid concurrent use without oncologist approval
• Iron supplements: ALA chelates metals; separate administration by at least 2 hours
• Alcohol: Reduces ALA efficacy and increases risk of lactic acidosis

Special Populations

• Pregnancy (Category B-equivalent): Limited human data; animal studies show no harm at therapeutic doses; use only if clearly needed
• Pediatric: Not recommended; reports of fatal overdose in children (particularly <6 years) — keep out of reach of children
• Diabetic neuropathy: Primary therapeutic population; well-studied at 600 mg/day IV or oral (NATHAN, SYDNEY, ALADIN trials)
• Renal impairment: No dose adjustment typically required; ALA is hepatically metabolized

Monitoring Recommendations

• Blood glucose monitoring, especially in diabetic patients initiating ALA
• Thyroid function tests with chronic use
• Hepatic function periodically with long-term use
• Thiamine levels in at-risk populations (alcoholism, malnutrition)
• Monitor for signs of hypoglycemia (tremor, sweating, confusion)

Regulatory Note: ALA is a dietary supplement in the US. In Germany, it is an approved prescription medication (Thioctacid) for diabetic polyneuropathy with extensive clinical trial data.

Pharmacokinetic Profile